for Health Care Providers
Table 6. Comparison of Sustained Virologic Response (SVR) Rates for Peginterferon Alfa-2a Combination Therapy, Peginterferon Alfa-2a Monotherapy, and Interferon Alfa Combination Therapy Given Over 48 wk
Back to Therapy for Previously Untreated Patients
|
*peginterferon alfa-2a 180 mcg/week plus ribavirin 1,000 or 1,200 mg/day
†peginterferon alfa-2a 180 mcg/week plus placebo ‡IFN 3 million U three times/week plus ribavirin 1,000 or 1,200 mg/day §Compared to interferon alfa plus ribavirin **Defined as >2 million copies/mL (COBAS AMPLICOR HCV Test, v. 2.0, sensitivity 100 copies/mL); equivalent to >800,000 IU/mL ¶Defined as ≤2 million copies/mL (COBAS AMPLICOR HCV Test, v. 2.0, sensitivity 100 copies/mL); equivalent to ≤800,000 IU/mL | |||
| PATIENT GROUP | SVR | ||
|---|---|---|---|
| Peginterferon alfa-2A (40 kDa) plus ribavirin* | Peginterferon alfa-2A (40 kDa) plus placebo† | Interferon alfa plus ribavirin‡ | |
| Overall | 56% (p<0.001)§ | 29% | 44% |
| HCV genotype 1 | 46% (p<0.01)§ | 21% | 36% |
| High viral titer** | 41% | 13% | 33% |
| Low viral titer¶ | 56% | 39% | 43% |
| HCV genotype 2, 3 | 76% (p<0.01) | 45% | 61% |
| High viral titer** | 74% | 40% | 58% |
| Low viral titer¶ | 81% | 58% | 65% |
